Clinical Trial

Educational Intervention on Oral Anticancer Agents for Community Pharmacists

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The overall aim of this study is to develop and test the feasibility and acceptability of an educational intervention for community pharmacists to provide support to patients receiving oral anticancer agents (OAAs) in the community. This pilot randomized controlled trial aims to evaluate the feasibility, acceptability, and preliminary effect of an educational intervention on the knowledge and confidence in managing OAAs among community pharmacists in Malaysia. PRIMARY OBJECTIVE • To evaluate the feasibility and acceptability of the educational intervention on OAAs among community pharmacists. SECONDARY OBJECTIVE • To obtain preliminary data on the effect of the educational intervention to improve community pharmacists' knowledge and confidence in managing OAAs. Participants will be randomly assigned to either the intervention group or control group in a 1:1 ratio using block randomization. After enrolling, participants will be asked to complete a baseline survey assessing their knowledge and confidence in managing OAAs. Immediately after completing the intervention and 4 weeks after the intervention, participants in the intervention group and control group will repeat the same questionnaire to assess changes in their knowledge and confidence. Results of this pilot study will inform the design of a larger study to test whether this intervention improves community pharmacists' knowledge and confidence. This research may help better prepare community pharmacists to provide high-quality care to patients receiving OAAs.
Protocol Amendment History 3 changes
notable Enrollment increased: 30 -> 40 participants 2026-07-15
notable Primary completion pushed: 2026-11 -> 2026-12 2026-07-15
minor Completion pushed: 2026-11 -> 2026-12 2026-07-15
Trial Details
NCT Number NCT07677176
Lead Sponsor Monash University Malaysia
Conditions Oral Anti-Tumor Drugs, Oral Antineoplastic Agents, Oral Anticancer Drugs
Enrollment 40 participants
Start Date 2026-08
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-14